Drugs / NSI-566
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01772810 | Aug 2014 → Jul 2018 | spinal cord injury | Neuralstem Inc. | Unknown | No outcome recorded |
| Phase 1 | NCT03296618 | Jun 2012 → May 2018 | cerebral infarction | Suzhou Neuralstem Biopharmaceuticals | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-01-20 | Palisade Bio | Results Seneca Biopharma, Inc. Announces Top Line Data from Phase 2 Clinical Study in China for the Treatment of Ischemic Stroke palisadebio.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-01-20 | Palisade Bio | Seneca Biopharma, Inc. Announces Top Line Data from Phase 2 Clinical Study in China for the Treatment of Ischemic Stroke palisadebio.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NSI-566 | “The primary outcome of the trial was to test the feasibility and safety of human spinal cord-derived neural stem cell (NSI-566) transplantation for the treatment of chronic...” PMID 39626671 ↗ Dec 2024 |
| Modality | Cell therapy | “human spinal cord-derived neural stem cell (NSI-566) transplantation” PMID 39626671 ↗ Dec 2024 |
| Route | Other | “stereotactic, intracranial injection” NCT03296618 ↗ |